Quality Compliance Professional
HumanaFull Time
Mid-level (3 to 4 years), Senior (5 to 8 years)
A minimum of a bachelor's degree in a scientific field or equivalent is required. Candidates must possess over 10 years of experience in Quality Compliance within the biopharmaceutical, pharmaceutical, biologics, or related life sciences sector. Strong experience in performing supplier audits, including GMP manufacturing, laboratories, warehouse and distribution, validation, and computerized systems, is essential.
The Associate Director of Quality Compliance will optimize and ensure the execution of quality processes and systems, collaborating with cross-functional teams to support GMP development and commercial launch activities. This role involves leading various aspects of Cytokinetics Quality Compliance, maintaining an effective function to ensure adherence to GMP/GDP regulations, and overseeing the GMP supplier quality program, including evaluations, risk assessments, qualifications, audits, and quality agreements. Responsibilities also include leading GMP/GDP and GxP computerized system supplier audits, ensuring quality agreement negotiations meet expectations and comply with regulations, maintaining supplier quality records, and advising management on regulatory surveillance. Additionally, the position supports inspection readiness for anticipated regulatory inspections and partner audits, monitors CMOs and contract labs for inspection status, and provides support for cross-functional teams and training. The role involves supporting the Quality Risk Management program, establishing and improving policies and systems for GMP activities oversight, providing technical support for investigations and training, developing and interpreting program metrics, representing Quality in cross-functional teams, and staying current with GxP regulations, providing impact assessments and recommendations for new requirements.
Develops drugs for muscle function disorders
Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.